Exponent, Inc. (NASDAQ:EXPO – Free Report) – William Blair lowered their Q2 2025 earnings estimates for shares of Exponent in a report issued on Friday, May 2nd. William Blair analyst A. Nicholas now anticipates that the business services provider will earn $0.48 per share for the quarter, down from their prior forecast of $0.55. The consensus estimate for Exponent’s current full-year earnings is $1.98 per share. William Blair also issued estimates for Exponent’s FY2025 earnings at $1.93 EPS, Q2 2026 earnings at $0.58 EPS, Q3 2026 earnings at $0.57 EPS, Q4 2026 earnings at $0.47 EPS and FY2026 earnings at $2.15 EPS.
Exponent (NASDAQ:EXPO – Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The business services provider reported $0.52 EPS for the quarter, beating the consensus estimate of $0.48 by $0.04. Exponent had a net margin of 19.52% and a return on equity of 27.27%. The business had revenue of $137.44 million for the quarter, compared to analysts’ expectations of $134.63 million. During the same period in the prior year, the firm earned $0.59 earnings per share. Exponent’s revenue was up .2% compared to the same quarter last year.
Exponent Stock Performance
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the company. Raymond James Financial Inc. acquired a new position in Exponent in the fourth quarter valued at about $55,131,000. Norges Bank bought a new position in shares of Exponent during the 4th quarter valued at about $52,381,000. Resona Asset Management Co. Ltd. bought a new position in shares of Exponent during the 4th quarter valued at about $38,538,000. BLI Banque de Luxembourg Investments acquired a new position in shares of Exponent in the 4th quarter valued at approximately $12,564,000. Finally, Barclays PLC increased its stake in Exponent by 88.5% during the 4th quarter. Barclays PLC now owns 181,921 shares of the business services provider’s stock worth $16,209,000 after purchasing an additional 85,395 shares in the last quarter. Institutional investors and hedge funds own 92.37% of the company’s stock.
Insider Activity
In other Exponent news, VP Richard Reiss sold 1,736 shares of the firm’s stock in a transaction dated Wednesday, February 26th. The stock was sold at an average price of $85.93, for a total transaction of $149,174.48. Following the transaction, the vice president now owns 1,800 shares in the company, valued at approximately $154,674. This trade represents a 49.10 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 2.10% of the company’s stock.
Exponent Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Friday, June 20th. Shareholders of record on Friday, June 6th will be given a dividend of $0.30 per share. The ex-dividend date is Friday, June 6th. This represents a $1.20 dividend on an annualized basis and a yield of 1.59%. Exponent’s payout ratio is presently 58.54%.
Exponent Company Profile
Exponent, Inc, together with its subsidiaries, operates as a science and engineering consulting company in the United States and internationally. The company operates in two segments, Engineering and Other Scientific, and Environmental and Health. The Engineering and Other Scientific segment provides services in the areas of biomechanics, biomedical engineering and sciences, buildings and structures, civil engineering, construction consulting, data sciences, electrical engineering and computer science, human factors, materials and corrosion engineering, mechanical engineering, polymer science and materials chemistry, thermal sciences, and vehicle engineering.
See Also
- Five stocks we like better than Exponent
- Stock Average Calculator
- 3 Mid-Cap Medical Stocks Outperforming the Market
- Stock Market Upgrades: What Are They?
- The Top-Ranked Insider Buys From April by Market Cap
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?
Receive News & Ratings for Exponent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exponent and related companies with MarketBeat.com's FREE daily email newsletter.